Submitted:
11 February 2025
Posted:
13 February 2025
You are already at the latest version
Abstract
Nigeria holds the unfortunate distinction of having the second-largest HIV epidemic globally, a complex and multifaceted challenge that demands sustained attention and resources. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) has been a cornerstone of Nigeria's HIV/AIDS response for two decades. Since its inception, PEPFAR has provided substantial financial and technical assistance, significantly shaping the landscape of HIV prevention, treatment, care, and support services in the country. However, the recent decision to cut PEPFAR funding poses a significant threat to the country's HIV/AIDS response. This review analyzes the contributions of PEPFAR to Nigeria's HIV/AIDS program, examine the potential impact of PEPFAR funding cuts on HIV prevention, treatment, care, and support services, explore the social and economic consequences of funding reductions, identify adaptive strategies and mitigation measures to address the funding gap and provide policy recommendations to strengthen Nigeria's HIV/AIDS response in the face of funding constraints.
Keywords:
1. Introduction
1.1. Background on Nigeria’s HIV Epidemic
1.2. Overview of PEPFAR’s Role in Nigeria’s HIV Response
1.3. Rationale for Reviewing the Impact of Funding Cuts
2. PEPFAR and Its Contributions to Nigeria’s HIV Program
2.1. Historical Overview, Key Objectives, and The Evolving Role of PEPFAR in Nigeria
- I.
- Scaling Up HIV Prevention, Treatment, and Care ServicesPEPFAR's strategy has centered on broad access to a full range of HIV/AIDS services. This includes providing free or low-cost antiretroviral treatment for individuals living with HIV, implementing focused prevention programs for high-risk groups, and offering healthcare support to lessen the effects of the disease.
- II.
- Reducing HIV Transmission RatesPrevention remains a core pillar of PEPFAR’s mission. The program has supported strategies such as voluntary medical male circumcision (VMMC), condom distribution, pre-exposure prophylaxis (PrEP), and prevention of mother-to-child transmission (PMTCT) to curb new HIV infections.
- III.
- Strengthening Healthcare Infrastructure and WorkforcePEPFAR has significantly contributed to improving healthcare delivery in Nigeria by funding the construction and renovation of healthcare facilities, training healthcare workers, and providing essential medical equipment. It has also invested in laboratory infrastructure for early diagnosis and monitoring of HIV/AIDS patients.
- IV.
- Enhancing Data Collection and Surveillance SystemsReliable data is crucial for monitoring progress in the fight against HIV/AIDS. PEPFAR has supported Nigeria in establishing electronic medical records, HIV surveillance systems, and data-driven decision-making to improve patient management and healthcare planning.
- V.
- Supporting Orphans and Vulnerable Children (OVC)Recognizing the social impact of HIV/AIDS, PEPFAR has invested in programs that provide support to children orphaned by AIDS and other vulnerable groups. This includes educational support, nutritional programs, and psychosocial services to reduce the economic and social burden on affected families.
- VI.
- Encouraging Country Ownership and SustainabilityOver time, PEPFAR has worked towards shifting ownership of HIV/AIDS programs to partner countries, including Nigeria, by fostering collaboration with local governments, civil society organizations, and the private sector. This transition aims to reduce dependence on external aid and ensure long-term sustainability of HIV/AIDS interventions.
- I.
- Phase 1 (2003–2008): Emergency Response Phase – Focused on scaling up ART, setting up HIV/AIDS programs, and increasing awareness.
- II.
- Phase 2 (2008–2014): Transition to Sustainability – Emphasized strengthening healthcare infrastructure and improving the efficiency of HIV programs.
- III.
- Phase 3 (2014–Present): Country Ownership and Epidemic Control – Focuses on building local capacity, enhancing cost-effectiveness, and ensuring long-term sustainability through increased Nigerian government and private sector involvement.
2.2. Achievements in Nigeria’s HIV Prevention and Treatment Efforts
- I.
- ART Scale-Up: PEPFAR funding has enabled a massive scale-up of ART, significantly increasing the number of Nigerians living with HIV who have access to life-saving medication (5). This scale-up has not only improved individual health outcomes but also contributed to preventing onward transmission of the virus.
- II.
- Prevention Interventions: PEPFAR has supported a range of evidence-based prevention interventions, including HIV testing and counseling, condom distribution, pre-exposure prophylaxis (PrEP) for at-risk populations, and targeted programs for key and vulnerable groups (2).
- III.
- PMTCT Services: PEPFAR has played a vital role in expanding access to prevention of mother-to-child transmission (PMTCT) services, contributing to a significant reduction in mother-to-child HIV transmission rates.
2.3. Key Interventions Supported by PEPFAR
- I.
- Healthcare Infrastructure: PEPFAR funding has supported the strengthening of healthcare infrastructure, including the renovation and equipping of health facilities, improving laboratory capacity for HIV diagnosis and viral load testing, and enhancing supply chain management for essential medicines (6).
- II.
- Capacity Building: PEPFAR has invested in training healthcare workers in HIV/AIDS care and management, building local expertise, and strengthening the capacity of Nigerian institutions to manage and implement HIV programs (7).
3. Implications of PEPFAR Funding Cuts
3.1. Impact on HIV Prevention Programs
3.2. Impact on HIV Treatment and Care
- I.
- ART disruptions and stockouts: Interruptions in the supply of ARV medications will jeopardize the health of individuals on treatment and increase the risk of drug resistance.
- II.
- Increased risk of drug resistance and treatment failure: Inconsistent access to ART can lead to treatment failure and the development of drug-resistant strains of HIV, making future treatment options more challenging and costly.
- III.
- Effect on maternal and child health services: Reduced funding for PMTCT services will increase the risk of mother-to-child transmission of HIV, jeopardizing the health of newborns.
3.3. Impact on Healthcare Infrastructure and Workforce
3.4. Social and Economic Consequences
- I.
- Increased HIV-related morbidity and mortality: Reduced access to treatment and care will lead to increased illness and death among people living with HIV.
- II.
- Socioeconomic burdens on affected communities: The burden of HIV-related illness and death will place a significant strain on families and communities, impacting productivity and economic development.
4. Adaptive Strategies and Mitigation Measures
4.1. Nigerian government’s response to funding cuts
4.2. Role of local and international organizations in sustaining HIV programs
4.3. Alternative funding mechanisms and partnerships
4.4. Community-led initiatives to bridge service gaps
5. Future Directions and Policy Recommendations
- I.
- Strengthening domestic healthcare financing for HIV programs: Increasing budgetary allocations to the health sector, prioritizing HIV/AIDS funding, and improving efficiency in resource allocation are crucial steps.
- II.
- Enhancing public-private partnerships for sustainable funding: Creating an enabling environment for public-private partnerships in the health sector can leverage private sector resources and expertise to support HIV programs.
- III.
- Improving efficiency in HIV service delivery: Streamlining service delivery models, integrating HIV services with other health services, and utilizing technology to improve efficiency can maximize the impact of limited resources.
- IV.
- Advocacy for the restoration of global health funding: Sustained advocacy efforts are needed to urge international donors to restore funding for global health programs, including PEPFAR, recognizing the critical role they play in combating global health challenges.
6. Conclusion
References
- UNAIDS. (2023). HIV/AIDS Statistics and Trends in Nigeria. Joint United Nations Programme on HIV/AIDS. Retrieved from https://www.unaids.org/en/regionscountries/countries/nigeria.
- Kaiser Family Foundation, 2024. The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Available at : https://www.kff.org/global-health-policy/fact-sheet/the-u-s-presidents-emergency-plan-for-aids-relief-pepfar/ (Accessed: January 30, 2025).
- PEPFAR. (2003). The U.S. President’s Emergency Plan for AIDS Relief: Five-Year Strategy Report. U.S. Department of State. Retrieved from https://www.state.gov/pepfar.
- PEPFAR Nigeria Report. (2023). PEPFAR’s Impact in Nigeria: Achievements, Challenges, and Future Directions. U.S. Embassy in Nigeria. Available at : https://ng.usembassy.gov/pepfar (Accessed: January 30, 2025).
- Eholie SP, Moh R, Benalycherif A, Gabillard D, Ello F, Messou E, Zoungrana J, Diallo I, Diallo M, Bado G, Cisse M, Maiga AI, Anzian A, Toni TD, Congo-Ouedraogo M, Toure-Kane C, Seydi M, Minta DK, Sawadogo A, Sangaré L, Drabo J, Karcher S, Le Carrou J, de Monteynard LA, Peytavin G, Gabassi A, Girard PM, Chaix ML, Anglaret X, Landman R; Thilao ANRS 12269 Study Group. Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study. Lancet HIV. 2019 Nov;6(11):e750-e759. [CrossRef] [PubMed]
- Centers for Disease Control and Prevention (CDC). (2022). The Impact of PEPFAR on Global HIV/AIDS Response. Retrieved from https://www.cdc.gov/globalhivtb/who-we-are/pepfar.html.
- Global Fund. (2022). Public-Private Partnerships in HIV/AIDS Response: Lessons from Nigeria. Retrieved from https://www.theglobalfund.org/en/.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
